CRMD Stock Analysis: CorMedix | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 690m USD | 12M Return: -22.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.3M
Qual. Beats: 0
Rev. Trend: 97.1%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CorMedix Inc. is a U.S.-based biopharmaceutical company that develops and commercializes therapeutic products for life-threatening diseases and conditions, with a particular focus on reducing infection risk in vulnerable patient populations. Its lead product candidate, DefenCath, is an antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections (CRBSIs) in adult kidney failure patients undergoing hemodialysis.
The company operates within the small-cap pharmaceuticals segment of the health care sector, a category that typically includes late-stage clinical and early-commercialization biopharmaceutical firms. CorMedix was incorporated in 2006 (originally as Picton Holding Company), adopted its current name in January 2007, and is headquartered in Parsippany, New Jersey, within the broader Northeastern U.S. pharmaceutical industry corridor. Its business model centers on bringing a single, specialized hospital-administered product through regulatory approval and into a niche market of dialysis-dependent patients, a population with elevated exposure to catheter-associated infections.
- DefenCath commercial sales ramp after FDA approval
- CMS reimbursement status determines hospital adoption pace
- Cash burn raises dilution risk through future equity offerings
| Net Income: 181.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.24 > 0.02 and ΔFCF/TA 33.19 > 1.0 |
| NWC/Revenue: 63.58% < 20% (prev 133.8%; Δ -70.24% < -1%) |
| CFO/TA 0.24 > 3% & CFO 197.7m > Net Income 181.0m |
| Net Debt (-28.9m) to EBITDA (212.7m): -0.14 < 3 |
| Current Ratio: 2.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (93.0m) vs 12m ago 34.81% < -2% |
| Gross Margin: 85.83% > 18% (prev 95.19%; Δ -9.36% > 0.5%) |
| Asset Turnover: 82.89% > 50% (prev 55.19%; Δ 27.70% > 0%) |
| Interest Coverage Ratio: 67.50 > 6 (EBIT TTM 187.8m / Interest Expense TTM 2.78m) |
| A: 0.31 (Total Current Assets 383.1m - Total Current Liabilities 128.8m) / Total Assets 815.6m |
| B: -0.17 (Retained Earnings -138.0m / Total Assets 815.6m) |
| C: 0.39 (EBIT TTM 187.8m / Avg Total Assets 482.6m) |
| D: 1.15 (Book Value of Equity 437.0m / Total Liabilities 378.6m) |
| Altman-Z'' = 5.32 = AAA |
| DSRI: 0.58 (Receivables 154.8m/54.6m, Revenue 400.1m/82.6m) |
| GMI: 1.11 (GM 95.19% / 85.83%) |
| AQI: 30.79 (AQ_t 0.52 / AQ_t-1 0.02) |
| SGI: 4.85 (Revenue 400.1m / 82.6m) |
| TATA: -0.02 (NI 181.0m - CFO 197.7m) / TA 815.6m) |
| Beneish M = 17.15 (Cap -4..+1) = D |
As of July 08, 2026, the stock is trading at USD 8.87 with a total of 841,519 shares traded. Over the past week, the price has changed by +16.10%, over one month by +3.86%, over three months by +23.71% and over the past year by -22.33%.
Current recommended Stop Loss: 8.20 (which is 7.6% or 1.7 ATR below the current price).
CorMedix has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy CRMD.
- StrongBuy: 3
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15.2 | 71.4% |
P/E Trailing = 4.0507
P/E Forward = 17.1233
P/S = 1.7237
P/B = 1.5689
Revenue TTM = 400.1m USD
EBIT TTM = 187.8m USD
EBITDA TTM = 212.7m USD
Long Term Debt = 144.9m USD (from longTermDebt, last quarter)
Short Term Debt = 1.45m USD (from shortTermDebt, last fiscal year)
Debt = 149.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.29m
Net Debt = -28.9m USD (calculated: Debt 149.2m - CCE 178.1m)
Enterprise Value = 660.7m USD (689.6m + Debt 149.2m - CCE 178.1m)
Interest Coverage Ratio = 67.50 (Ebit TTM 187.8m / Interest Expense TTM 2.78m)
EV/FCF = 3.36x (Enterprise Value 660.7m / FCF TTM 196.4m)
FCF Yield = 29.73% (FCF TTM 196.4m / Enterprise Value 660.7m)
FCF Margin = 49.09% (FCF TTM 196.4m / Revenue TTM 400.1m)
Net Margin = 45.25% (Net Income TTM 181.0m / Revenue TTM 400.1m)
Gross Margin = 85.83% ((Revenue TTM 400.1m - Cost of Revenue TTM 56.7m) / Revenue TTM)
Gross Margin QoQ = 82.50% (prev 83.43%)
Tobins Q-Ratio = 0.81 (Enterprise Value 660.7m / Total Assets 815.6m)
Interest Expense / Debt = 1.86% (Interest Expense 2.78m / Debt 149.2m)
Taxrate = 2.16% (4.00m / 185.0m)
NOPAT = 183.7m (EBIT 187.8m * (1 - 2.16%))
Current Ratio = 2.98 (Total Current Assets 383.1m / Total Current Liabilities 128.8m)
Debt / Equity = 0.34 (Debt 149.2m / totalStockholderEquity, last quarter 437.0m)
Debt / EBITDA = -0.14 (Net Debt -28.9m / EBITDA 212.7m)
Debt / FCF = -0.15 (Net Debt -28.9m / FCF TTM 196.4m)
Total Stockholder Equity = 359.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 37.51% (Net Income 181.0m / Total Assets 815.6m)
RoE = 50.38% (Net Income TTM 181.0m / Total Stockholder Equity 359.3m)
RoCE = 37.25% (EBIT 187.8m / Capital Employed (Equity 359.3m + L.T.Debt 144.9m))
RoIC = 27.49% (NOPAT 183.7m / Invested Capital 668.3m)
WACC = 8.37% (E(689.6m)/V(838.8m) * Re(9.79%) + D(149.2m)/V(838.8m) * Rd(1.86%) * (1-Tc(0.02)))
Discount Rate = 9.79% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 23.92%
[DCF] Terminal Value 75.36% ; FCFF base≈196.4m ; Y1≈197.2m ; Y5≈208.9m
[DCF] Fair Price = 41.62 (EV 3.24b - Net Debt -28.9m = Equity 3.27b / Shares 78.5m; r=8.37% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.04 | # QB: 0
Revenue Correlation: 97.10 | Revenue CAGR: 4.63k% | SUE: 3.67 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.23 | Chg30d=-15.55% | Revisions=+12% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.09 | Chg30d=-68.76% | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=0.50 | Chg30d=-2.23% | Revisions=+0% | GrowthEPS=-75.5% | GrowthRev=+7.2%
EPS next Year (2027-12-31): EPS=0.09 | Chg30d=-59.32% | Revisions=-57% | GrowthEPS=-82.8% | GrowthRev=-14.7%
[Analyst] Revisions Ratio: -15% (up=7, down=10)